A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2016
At a glance
- Drugs Vatelizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Sponsors Sanofi Genzyme
- 12 Jul 2016 Status changed from active, no longer recruiting to discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.
- 02 May 2016 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
- 02 May 2016 Time frame for primary end points has been modified .